CV Sciences Inc(OTCMKTS:CVSI) continues to trade big volume and provide Investors with many great trade opportunities. The stock popped to $1 leading up to the elections and dropped with the rest of the sector after Trump one on a misguided perception that he would be bad for the markets; the opposite has turned out to be true of course.
CVSI is another pot stock that was swept up in the pot stock boom that has quickly turned into a multi-billion dollar massive growth market that is sweeping across the US and Canada with many new states legalizing the drug including California, Nevada, Maine, and Massachusetts on November 8. Medical marijuana products in the U.S. alone are projected to generate an estimated $30-35 Billion in revenue by 2020.
CV Sciences Inc(OTCMKTS:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.
In December of last year CVSI acquired CanX and commenced its preclinical drug development program during the second quarter of 2016. CVSI drug development efforts include pursuing synthetic-based Cannabidiol drug candidates in areas that have potential to provide significant improvements in therapeutic patient treatments with sizable addressable markets.
In August the Company reported Q2 financial results. CEO Michael Mona, Jr. stated “During the second quarter, we continued to generate strong performance from our consumer products division, as the distribution of our branded consumer products increased to 705 retail locations as of June 30, 2016, compared to the 120 retail locations a year ago. We have seen a strong market acceptance and an increase in demand for our consumer products with sales of $2.5 million during the three months ended June 30, 2016, up from sales of $2.4 million for the same period last year. Given our established position as a market leader in CBD consumer products, we have pivoted our corporate strategy to include the development and commercialization.”
CVSI also reported on its preclinical drug development program during the second quarter of 2016. The Company’s drug development efforts include pursuing synthetic-based Cannabidiol (“CBD”) drug candidates in areas that have potential to provide significant improvements in therapeutic patient treatments with sizable addressable markets.
To Find out the inside Scoop on CVSI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Natural Products Sales Channel Expands. The Company expanded its education program and marketing efforts in partnership with broker relationships and physician educators to increase this sales channel, addressing the $35 billion U.S. Natural Products industry. As of June 30, 2016, the Company continued its expansion in the Natural Products sales channel with placement into 705 stores.
Company Rebranding Continues. In June 2016, CV Sciences announced that Financial Industry Regulatory Authority (“FINRA”) had approved a change in the trading symbol for the Company’s common stock to “CVSI.” The Company’s common stock formerly traded under the symbol “CANV.”
On December 20 CVSI provided comments from its management with regards to the MLB’s recent ban on smokeless chewing tobacco for new players. Beginning this upcoming season, cities that include San Francisco, Boston, and Los Angeles will ban smokeless tobacco in the big-league ballparks and other sports venues. The city councils of Chicago and New York recently approved similar prohibitions on smokeless tobacco for Wrigley Field, U.S. Cellular Field, Citi Field and Yankee Stadium.
Michael Mona, Jr., President and CEO of CV Sciences commented, “We applaud baseball’s new labor agreement that prohibits all new players from using smokeless tobacco, like chew, dip and snuff. The recent death of former San Diego Padres Hall of Famer Tony Gwynn has highlighted the seriousness of the issue. Mr. Gwynn attributed his long struggle with salivary gland cancer directly to his many years of chewing tobacco.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $24 million market valuation CVSI does have $1.4 million in the treasury and significant sales reporting $4,910,434 revenues for the 6 months ended June 10, 2016. CVSI is an exciting story developing in small caps; the Company operates a drug development as well as a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors that is doing big sales numbers. We will be updating on CVSI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CVSI.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in CVSI either long or short and we have not been compensated for this article.